Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

By sjmartinez • September 7, 2023

André F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, D Tripathy, Lu YS, Lteif A, Taran T, Babbar N, Slamon D, Arteaga CL. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. 2023 Sep 4:S0923-7534(23)00826-8. doi: 10.1016/j.annonc.2023.08.011. Epub ahead of print. PMID: 37673211.

Tags: Advanced breast cancer, biomarkers, CDK4/6 inhibitor, Hematology/Oncology, overall survival, Publications, ribociclib

Characteristics of clinical trials associated with appeal and return on investment to participants, A Review and Framework

Fernandez Turizo MJ, Velez MA, Glenn B, Cummings AL, Segarra-Vazquez B, Gorbatov S, Park SJ, Shen C, Lind-Lebuffe JP, Unger JM, Garon EB. Characteristics of[...]

IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation

Sharma G, Gutierrez M, Jones AE, Kapoor S, Jaiswal AK, Neeb ZT, Rios A, Dorairaj P, Thaxton ML, Lin TL, Tran TM, Kabbani LES, Ritter[...]

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch[...]